Pharma

Your Article Summary

See Latest Articles

Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09

The US Food and Drug Administration has approved Valturna tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system, an important regulator of blood pressure. This is the first approval for Valturna, which is indicated for the treatment of high blood pressure in patients not adequately controlled on aliskiren or angiotensin receptor blocker monotherapy and as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09

Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder
Genzyme, 11/19/09

Par pharmaceutical receives final approval to market generic ultram er
Par Pharmaceutical, 11/17/09

 See all of Drug/Product Approvals